UK NSC Publishes Groundbreaking Guidance on Emerging Cancer Screening Technologies
The UK National Screening Committee (UK NSC) has released two new position statements that set clear standards for evaluating multicancer detection tests and the use of surrogate outcomes in cancer screening trials. Developed with significant input from researchers at the University of Warwick, the statements address the rapid growth in interest in new screening technologies and aim to ensure robust evidence underpins any future programme decisions.
Published in the BMJ on 26 May 2026, the documents provide principles for researchers, test developers and funders. They emphasise that while surrogate outcomes can support evaluations, mortality remains the definitive measure, and that multicancer detection tests require rigorous, use-case-specific evidence before any consideration for population screening.
University of Warwick Researchers Play Central Role
Academics from the University of Warwick contributed substantially to both statements. Their work highlights the importance of academic expertise in shaping national policy on screening. The involvement underscores how UK universities continue to drive evidence-based advancements in public health research.
Professor Bethany Shinkins and colleagues outlined consensus principles for multicancer detection tests, stressing that evidence requirements must align with the intended use—whether population-wide screening, high-risk groups, or alongside existing programmes for breast, bowel and cervical cancer.
Key Principles on Surrogate Outcomes in Screening Trials
The first statement addresses surrogate outcomes such as reductions in late-stage disease. The UK NSC position is that these can inform evaluations as part of standard assessments of benefits and harms. However, they cannot yet replace cancer mortality as the definitive trial outcome.
Reliable, screening-specific methods to confidently use surrogates in place of mortality do not currently exist. It remains uncertain whether improvements in surrogates consistently translate into mortality reductions across different cancer types.
Photo by Gary Edmonstone on Unsplash
Evidence Requirements for Multicancer Detection Tests
The second statement focuses on multicancer detection (MCD) tests, also known as multicancer early detection (MCED) tests. It sets out that developers must clearly specify the intended use from the outset, as scaling back or withdrawing an established screening programme is extremely difficult.
Evidence must demonstrate benefits and harms in the specific screening context, with particular attention to test performance, false positives, overdiagnosis and downstream clinical pathways.
Implications for UK Higher Education and Research
These position statements provide a clear framework that UK universities and research institutions can use to design future studies. They reinforce the need for rigorous, independent academic research in screening evaluation.
Opportunities arise for PhD and postdoctoral researchers in epidemiology, health technology assessment and cancer screening at institutions such as Warwick and other Russell Group universities.
Broader Context for Cancer Screening Research in the UK
The UK NSC statements arrive at a time of growing international interest in multicancer detection technologies. They align with the committee’s established role in advising ministers on screening programmes across England, Scotland, Wales and Northern Ireland.
Academic contributions ensure that policy remains grounded in the highest standards of evidence, supporting the UK’s reputation for world-leading public health research.
Photo by Margaret Young on Unsplash
Next Steps for Researchers and Institutions
Universities are encouraged to align grant applications and trial designs with the new principles. The statements will inform funding decisions by bodies such as the National Institute for Health and Care Research (NIHR) and Cancer Research UK.
Further details and the full statements are available on the BMJ website.